Poly™ - A Promising Drug Delivery Platform
Creative Biolabs has extensive experience in vaccine development and has developed a variety of vaccine delivery platforms for efficient delivery of vaccines. Poly™ is a poly(2-oxazoline)-based platform for the delivery of various types of drugs, including vaccines.
Poly™
2-oxazolines have a cationic ring-opening polymerization reaction which makes it possible to simply and directly synthesize a series of well-defined polymers, i.e. the function of the terminal groups can be controlled during the initiation and termination steps of the synthesis. Moreover, poly(2-oxazoline) can be adjusted by changing the side chain of the 2-oxazoline monomer. Therefore, in recent years, poly(2-oxazoline) has been widely used in biopharmaceuticals because of their biocompatibility and behavior similar to poly(ethylene oxide) (PEO). The incorporation of a drug onto a polymer is a commonly used strategy in drug discovery to increase the water solubility of the drug as well as to extend the circulation time in the body.
Poly(2-oxazoline) is a water-soluble, low-viscosity polymer whose synthetic starting materials are safe and readily available. The technical principle of Poly™-drug conjugate is simply that we use a metal-catalyzed click chemistry method that uses pendent alkyne groups to incorporate the drug into the polymer backbone. Specifically, we use the initiator, 2-ethyl-2-oxazoline, 2-pentynyl-2-oxazoline to carry out the reaction at a certain temperature to prepare pendent Poly™, which will then be purified by ion exchange chromatography according to the characteristics of -COOH at the terminus of the polymer. Once Poly™ is prepared, we incorporated the drug containing azide onto Poly™ using the single-step Cu(I)-catalyzed click chemistry method at the pendent alkyne site. The release of the drug can be precisely tuned by adjusting the nature of the linker of the drug.
Fig.1 Conjugate formed between poly(2-ethyl-2-oxazoline) and a cyclic RGD peptide. (R. Hoogenboom, 2009)
Advantages of Poly™ Conjugated Drug
- Improved safety over PEG due to little cellular uptake in non-target tissues
- No immunogenicity
- Able to target cells
- Flexible payload and controlled release of drug
- Easy to synthesize, stable, renal clearance
- Ability to be applied to various types of vaccines and drugs
Creative Biolabs, with its leading research team from around the world, is second to none in vaccine development, not only because of its good service attitude but more importantly because of its excellent professional ability to bring the services of highest quality and reliability to its customers. The Poly™ platform we developed is one of our professional capabilities. The platform not only delivers vaccines efficiently but also provides good safety and productivity, while ensuring the efficacy and cost of development of the drugs delivered.
Reference
- Richard Hoogenboom; (2009). “Poly(2-oxazoline)s: A Polymer Class with Numerous Potential Applications.” Angew. Chem. Int. Ed. 48, 7978-7994.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
